Journal
NATURE REVIEWS IMMUNOLOGY
Volume 18, Issue 3, Pages 212-219Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nri.2017.89
Keywords
-
Categories
Funding
- Institute of Chemical immunology [024.002.009]
- Netherlands Organisation for Scientific Research (NWO) Spinoza Prize
- European Research Council advanced grant PATHFINDER [269019]
- KWO of the Dutch Cancer Society [2009-4402]
Ask authors/readers for more resources
Cancer immunotherapy can successfully promote long-term anticancer immune responses, although there is still only a limited number of patients who benefit from such treatment, and it can sometimes have severe treatment-associated adverse events. Compared with systemic immunomodulation, local immunomodulation may enable more effective treatment at lower doses and, at the same time, prevent systemic toxicity. Local delivery of engineered three-dimensional scaffolds may fulfil this role by acting as synthetic immune niches that boost anticancer immunity. In this Opinion article, we highlight the potential of scaffold-based adoptive cell transfer and scaffold-based cancer vaccines that, although applied locally, can promote systemic antitumour immunity. Furthermore, we discuss how scaffold-based cancer immunotherapy may contribute to the development of the next generation of cancer treatments.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available